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Introduction
Long non-coding RNAs (lncRNAs) are RNA 
transcripts characterized by a length about 200 nucleotides 
or more in length. These RNA molecules have been shown 
to regulate the gene expression at the transcriptional 
and post-transcriptional levels (Beermann et al., 2016; 
Parikshak et al., 2016; Adams et al., 2017; Qian et al., 
2017). 
Until recently, a number of studies have reported the 
aberrant expression of lncRNAs in various malignancies 
(Beermann et al., 2016; Parikshak et al., 2016; Adams et 
al., 2017; Qian et al., 2017). In the last decades, numerous 
studies have investigated the role of lncRNAs in cancer 
development and progression (Cao, 2014; Karlsson 
and Baccarelli., 2016). Accordingly, it has been shown 
that lncRNAs involve in a wide range of biological and 
cellular processes, including, cell growth, proliferation, 
differentiation, migration, invasion and apoptosis. Also, it 
has been demonstrated that lncRNAs are correlated with 
clinicopathological features in cancer patients and could be 
served as potential diagnostic and prognostic biomarkers 
(Wang et al., 2016; Chandra Gupta and Nandan Tripathi., 
2017; Li et al., 2017). 
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Prostate cancer–associated lncRNA transcripts 1 
(PCAT-1), encoded by the PCAT-1 gene mapped on 
chromosome 8q24.21, is a long intergenic non-coding 
RNA (Shi et al., 2015; Yan et al., 2015). This lncRNA 
firstly was annotated by RNA sequencing of prostate 
tissues and cells lines and transcriptome analysis (Prensner, 
Iyer et al. 2011). The functional studies confirmed that 
lncRNA PCAT-1 could promote cell proliferation through 
binding to polycomb repressive complex 2 (PCR2) as a 
transcriptional repressor (Saus et al., 2016).
Moreover, a number of clinical investigations 
promoted the diagnostic and prognostic value of PCAT-1 
in various cancers. PCAT-1 has also been suggested 
as lncRNA that is related to overall survival (OS) in 
various carcinomas, including colorectal, gastric, breast, 
bladder, lung cancers, andmultiple myeloma, extrahepatic 
cholangiocarcinoma (ECC), hepatocellular carcinoma and 
esophageal squamous cell carcinoma (ESCC) (Ge et al., 
2013; Shi et al., 2015; Yan et al., 2015; Qin et al., 2016; Cui 
et al., 2017). Altogether, PCAT-1 was supported that act 
as a prognostic marker and a therapeutic target for cancer 
therapy (Evans et al., 2014; Shi et al., 2015; Qiao et al., 
2017; Shen et al., 2017; Zhang et al., 2017). Nevertheless, 
there are some limitations, including study design and 
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insufficient sample size can be lead to inaccurate results. 
In addition, it is vital to investigate some important risk 
factors related to PCAT-1 in various malignancies. 
Ever since, no meta-analysis study has been completed 
to explore the clinical value of PCAT-1 as a biomarker 
for various cancers. Thus, we carried out the present 
systematic review and meta-analysis study to evaluate the 
biological and clinical significance of PCAT-1 in several 
malignancies.
Biological significance
Experimental investigations revealed that PCAT-1 
exerts a vital function in oncogenic signaling pathways 
related to cell proliferation. Recently, the experimental 
investigations revealed that lncRNA PCAT-1 can increase 
the proliferation, metastasis and invasion of cervical 
cancer cells (Ma et al., 2018). 
The biological role of lncRNA PCAT-1 in the 
regulation of proto-oncogene c-Myc in prostate cancer 
has recently been reported. The tumorigenic effect of 
lnc-PCAT-1 in colorectal cancer (CRC) through inhibiting 
the c-Myc has been described (Qiao et al., 2017). Also, 
this lncRNA could promote CRC cell migration and 
invasiveness, as confirmed by the increased viability and 
induced apoptosis (Qiao et al., 2018).  Altogether, it was 
suggested that PCAT-1 is an important lncRNA in the 
regulation of the c-Myc expression and corresponding 
proliferative signaling pathways (Evans et al., 2014). 
In esophageal squamous cell carcinoma (ESCC), 
lnc-PCAT-1 has been demonstrated to promote cancer 
cell proliferation and growth, indicating it as a therapeutic 
target for ESCC (Zhen et al., 2018).
Moreover, the functional studies showed that lnc-
PCAT-1 may increase cells proliferation, migration and 
invasion in osteosarcoma by interacting with EZH2 and 
repressing p21 gene. These findings suggest lnc-PCAT-1 
as a oncogenic mediator in osteosarcoma carcinogenesis 
(Huang et al., 2018).
Clinical significance
The relationship between the dysregulation of PCAT-1 
and the progression of carcinoma have been investigated 
in colorectal and gastric cancers, hepatocellular and 
esophageal squamous cell carcinoma (Ge et al., 2013; Shi 
et al., 2015; Yan et al., 2015; Qin et al., 2016; Cui et al., 
2017). Moreover, the aberrant expression of this lncRNA 
was correlated with clinicopathological features in a 
number of malignancies, indicating it as a potential marker 
for early cancer detection (Shi et al., 2015; Yan et al., 
2015; Qin et al., 2016; Cui et al., 2017). Dysregulation of 
lnc-PCAT-1 also designated as an independent prognostic 
factor for the overall survival (OS) rate of cancer patients 




Two independent reviewers performed an extensive 
search in several electronic databases such as Springer, 
Medline, BioMed Central, ScienceDirect, Scopus, 
Embase, Web of Science, CNKI, CBM, Cochrane Central 
Register of Controlled Trials (CENTRAL) Cochrane 
Library, China National Knowledge Infrastructure and 
Chinese WanFang database for the published studies up to 
December 2017. Search strategy was based on the words 
presented in Table 1.
The applied search strategy was based on both 
medical subject heading terms and free-text words in 
order to enhance the sensitivity of the database search. 
The main keywords selected for the search were used 
as follows: “PCAT-1 and cancer”, “lnc-PCAT-1 and 
cancer”, “long non-coding RNA PCAT-1”, “lncRNA 
PCAT-1”, “PCAT-1”, “prostate cancer associated transcript 
1”. Furthermore, all findings presenting as abstract in 
conferences were excluded from the study. The extraction 
and evaluation of relevant eligible studies were completed 
by two independent investigators.
In the meantime, all reference lists of related articles 
were also examined in order to conclude the eligible 
studies and also the recovered references were disregarded 
due to duplication. Moreover, the titles, abstracts, as well 
as full texts were carefully read to remove unrelated 
studies with no eligibility criteria.
Inclusion and exclusion criteria
Inclusion criteria: 1) A relationship of dichotomous 
PCAT-1 expression level with prognosis and diagnosis 
factors, clinical consequence in cancer patients; 2) A 
potential role of PCAT-1 specifically in the pathogenesis 
of any type of cancers; 3) A hazard ratios (HRs) and 95% 
its confidence intervals (CIs) for overall survival (Cox 
proportional hazard analysis, Kaplan–Meier method); 4) 
Published in English.
Exclusion criteria: 1) Studies of non dichotomous 
lncRNA PCAT-1 expression or absence of survival 
outcome; 2) Multiple duplicated articles; 3) Letters and 
conference abstracts.
Data analysis method
STATA version 14.0 (Stata Corporation, College 
Station, TX) was used for statistical analysis. Also, 
heterogeneity between the studies was performed by 
chi square and I2 tests and the level of significance for 
statistical tests was 0.05 based on Cochran-Q value 
(showing heterogeneity). We applied the fixed effect 
model when the data were homogeneous. When the cause 
of heterogeneity was not known, the random effect model 
was used. Lastly, the results of the studies were pooled 
and an overall effect size was given. It is worth noting that 
meta-analyses were performed when there are at least 3 
studies related to reported data. Moreover, Begg’s test was 
carried out for recognizing publication bias.
Results
Biological and clinical relevance of lnc PCAT-1
Our focus was on the studies indicated lncRNA 
PCAT-1 as a potential effector in cellular process as well 
as its role as a clinical biomarker for several cancers. 
Table 2 shows the biological and clinical significance of 
lnc-PCAT-1 in a number of cancers.
Asian Pacific Journal of Cancer Prevention, Vol 20 669
DOI:10.31557/APJCP.2019.20.3.667
Role of Long Non-Coding RNA PCAT-1 in Cancer 
Relationship between lncRNA PCAT-1 expression and 
clinical outcome
A total of 996 patients from 5 studies were included 
for meta-analysis that all these studies were completed 
in Chinese population. Five different cancer types were 
including colorectal cancer (Ge et al., 2013), gastric 
cancer (Cui et al., 2017), hepatocellular carcinoma (Yan 
et al., 2015), Esophageal squamous cell carcinoma (Shi et 
al., 2015; Qin et al., 2016). The included cancer patients 
were classified into two groups (low/ high) based on the 
expression level of PCAT-1 for the median and ROC 
values. 
The characteristics of the study
First, 1460 articles were extracted from electronic 
databases and after removing duplicate articles, 980 
articles were screened according to a potential prognostic 
or diagnostic role of lncRNA PCAT-1 in cancers. Then, 
the full texts of 50 articles werereviewed and evaluated, 
5 articles were finalized to meta-analysis because having 
aforementioned eligible inclusion criteria (Ge et al., 2013; 
Shi et al., 2015; Yan et al., 2015; Qin et al., 2016; Cui et al., 
2017) (Figure 1). This Figure shows the stages of finding 
the appropriate articles for the current study.
Database Search terms
MEDLINE ("cancer"[Mesh] OR "tumor"[tiab] OR "malignancy"[tiab] OR "neoplasm"[tiab] OR " adenocarcinoma"[tiab] 
AND ("long noncoding RNA"[MeSH Terms] OR "long non-coding RNA"[tiab] OR "Long non-coding 
RNA"[tiab] OR "Long noncoding RNAs"[tiab] OR " Long noncoding lncRNA"[tiab] OR " Long noncoding 
lncRNAs"[tiab] OR "long noncoding lncRNAs "[tiab] OR " long noncoding lncRNAs "[tiab] AND ("Prostate 
cancer-associated lncRNA transcripts 1"[MeSH Terms] OR "Prostate cancer-associated lncRNA transcripts 
1"[tiab] OR "PCAT-1"[tiab] OR "PCAT1"[tiab] OR "plasma"[tiab] OR "serum"[tiab] OR "circulating long 
noncoding lncRNA "[tiab] OR " blood stream"[tiab])
EMBASE 1- exp" cancer"/ or ("tumor" OR "malignancy" OR "neoplasm "[tiab] OR "adenocarcinoma").ti,ab. 
2- exp "long non-coding lncRNA"/ or "long noncoding lncRNA" OR "Long noncoding lncRNA" OR "Long 
non-coding lncRNAs" OR " Long noncoding lncRNA" OR " Long noncoding lncRNAs" OR " long noncoding 
lncRNA "AND "Prostate cancer-associated lncRNA transcripts 1"/ or "PCAT1" OR "PCAT-1" OR "plasma" 
OR "serum" OR " long noncoding lncRNA " OR "blood stream").ti,ab.
3- 1 & 2
SCOPUS ((TITLE-ABS-KEY (cancer) OR TITLE-ABS-KEY (adenocarcinoma) OR TITLE-ABS-KEY (malignany) OR 
TITLE-ABS-KEY (neoplasm) OR TITLE-ABS-KEY (plasma)))
AND ((TITLE-ABS-KEY (Prostate cancer-associated lncRNA transcripts 1) OR TITLE-ABS-KEY (PCAT-1) 
OR TITLE-ABS-KEY (PCAT1) AND ((TITLE-ABS-KEY (serum) OR  TITLE-ABS-KEY (blood stream) OR 
TITLE-ABS-KEY (plasma) OR TITLE-ABS-KEY (circulating) OR TITLE-ABS-KEY (lnc RNA) OR TITLE-
ABS-KEY (cancer) OR TITLE-ABS-KEY (circulating lnc RNA) OR TITLE-ABS-KEY (plasma lncRNA) OR 
TITLE-ABS-KEY (circulation OR TITLE-ABS-KEY (circulating long noncoding RNA) OR TITLE-ABS-
KEY (Long noncoding RNA)
Table 1. Queries Used in Medline, Embase and Scopus
Figure 1. Flowchart of the Meta-Analysis
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Figure 2 shows the quality of the included studies has 
been assessed by QUADAS-2. As it is shown, all studied 
articles were on the upper middle quality. However, there 
is an obvious major bias in these included articles. It 
means that, there are clear weaknesses in the ‘‘index text,’’ 
which was 65% for these eligible studies.
Table 3 shows the main characteristics of patient 
cancers.
Type of cancer Biological (Ref) Clinical (Ref)
Hepatocellular carcinoma Promoting cell invasion and metastasis through 
inhibiting miR-129-5p (Zhang et al., 2017).
Increasing cell proliferation and migration, decreasing 
apoptosis (Wen et al., 2016).
Potential candidate for HCC diagnosis and treatment 
(Zhang et al., 2017).
Candidate biomarker for HCC therapeutic strategies 
(Wen, Xu et al. 2016).
Potential diagnostic tool or therapeutic target for 
HCC (Zhang et al., 2016).
Gastric cancer Promoting cell proliferation, migration and invasion 
through regulating CDKN1A (Bi et al., 2017).
Potential diagnostic marker of gastric cancer (Bi et 
al., 2017).
Colorectal cancer Promoting cell invasion, metastatic potential and drug 
resistance through c-Myc(Qiao et al., 2017).
Increasing cell proliferation (Qiao et al., 2017).
Potential candidate biomarker for CRC (Qiao et al., 
2017).
Breast cancer Correlating with clinical characteristics and as a 
biomarker for breast cancer (Sarrafzadeh et al., 
2017).
Prostate cancer Promoting proliferation, migration and invasion, 
inhibiting apoptosis (Xu et al., 2017).
Increasing cell proliferation through modulating cMyc 
function (Evans et al., 2014). 
Acting as oncogenic lncRNA in prostatecancer 
proliferation through cMyc(Prensner, Chen et al., 
2014).
Regulating BRCA2 levels (Prensner et al., 2011, 
Prensner et al., 2011) and homologous recombination 
(Prensner et al., 2014).
As a predictive biomarker (PCAT-1) was applied in 
PARP1 inhibitor therapy of patients (Prensner et al., 
2014).
As key aspects of disease biology and clinically 
important biomarkers (Prensner et al., 2011; 
Prensner et al., 2011).
Lung cancer Promoting cell proliferation, migration and invasion 
(Zhao et al., 2015).
Potential therapeutic target (Zhao et al., 2015).
Bladder cancer Decreasing cell proliferation and increasing cell 
apoptosis (Liu et al., 2015).
Acting as a biomarker for predicting bladder cancer 
(Liu et al., 2015; Xu et al., 2017).
Cervical cancer Increasing cell proliferation, metastasis and invasion 
(Ma et al., 2018).
Osteosarcoma Increasing cell proliferation, migration and invasion 
by interacting with EZH2 and repressing p21 gene 
(Huang et al., 2018).
Eusophagus squamous cell 
carcinoma
Promoting cancer cell proliferation and growth (Zhen., 
2018).
Multiple myeloma Correlating with the clinicopathologic features and 




Promoting cell proliferation and inducing cell 
apoptosis. Acting as a competing endogenous RNA 
(ceRNA) against miR-122. 
Regulating WNT1 expression via miR-122 (Zhang et 
al., 2017).
Table 2. Description of Potential Prognostic lncRNA Markers in Colorectal Cancer
CRC, colorectal cancer; EMT, Epithelial-mesenchymaltransition; lincRNA, long intergenic non-coding RNA, MM, Multiple myeloma; ECC, 
Extrahepatic cholangiocarcinoma; PARP-1, Poly [ADP-ribose] polymerase 1; NSCLC, Non-small-cell lung carcinoma.




Test method Cut off Outcome 
measure
HR estimation Follow up 
Months
Ge 2013 China CRC 189 qRT-PCR ROC OS Directly ~90
Yan 2015 China HCC 117 qRT-PCR Median value OS Directly ~60
Shi 2015 China ESCC 194 qRT-PCR Median value OS Directly ~60
Qin 2016 China ESCC 321 PCR, Sequencing Median value OS Directly ~60
Cui 2017 China GC 175 qRT-PCR Median value OS Directly ~60
CRC, Colorectal cancer; HCC, Hepatocellular carcinoma; ESCC, Esophageal squamous cell carcinoma; GC, Gastric cancer; OS, overall survival; 
ROC, Receiver Operating Characteristic
Table 3. Main Characteristics of the Include Studies for Clinical Studies
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Risk of Bias
In the present study there was no publication bias. 
According to Begg’s test (Z=-0.49; p=0.25) no publication 
bias was detected.
Meta-analysis results 
The relationship between PCAT-1 and OS
Five articles, including 996 cancer patients were 
identified as selected studies in relationship with the 
expression level of PCAT-1 and overall survival (OS) 
(Figure 3). Because of heterogeneity among studies, the 
random effect model was applied to calculate the overall 
hazard (I2= 81.4%, P-value<0.001). 
The overall and pooled results revealed that the high 
expression level of PCAT1 was significantly related to 
shorter overall survival in cancer patients (HR =1.9, 95% 
CI: 1.13-3.18, P<0.001).
Diagnostic value of PCAT-1 expression
Five studies, including 996 cancer patients and 300 
patients with low level of PCAT-1 expression and 551 
patients with high level of PCAT-1 expression were 
subjected to analyse the diagnostic value of PCAT-1 
expression (Ge et al., 2013; Shi et al., 2015; Yan et al., 
2015; Qin et al., 2016; Cui et al., 2017). Table 4 shows 
the sensitivity and specificity of five studies related to 
the evaluated tumor types: ESCC, GC, HCC, and CRC. 
Figure 4 reveals the Forest plots of sensitivity (SEN) 
and specificity (SPE) of PCAT-1 expression for tumor 
diagnosis.
Significant heterogeneity among the studies was 
observed with respect to both sensitivity and specificity 
(I2=0.81 and I2=0.79, respectively). Therefore, 
random-effects model was performed to summarize the 
diagnostic parameters. Moreover, pooled sensitivity and 
Figure 2. The Flow Diagram of Quality Assessment Using the QUADAS Check List Based on “Risk of Bias’’ and 
‘‘Applicability Concerns”
Figure 3. Forest Plot for the Relationships between PCAT-1 Expression and OS
Study Sample size SE (%) SP (%) AUC 95% CI Sample
Ge 2013 58 (50)* 78 54 0.71 0.62-0.76 Tissue
Yan 2015 58 (59) 61 63 0.66 0.57-0.71 Tissue
Shi 2015 26(104) 58 70 0.7 0.63-0.74 Tissue
Qin 2016 71 (250) 58 60 0.62 0.58-0.66 Tissue
Cui 2017 87 (88) 42 81 0.65 0.57-0.69 Tissue
*, low expression (high expression)
Table 4. Summary of PCAT-1 Expression Levels as Biomarkerof Predict Prognosis in Cancers
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specificity values were 0.59 (95% CI, 0.46–0.73) and 
0.66 (95%CI, 0.46– 0.73), respectively. Furthermore, the 
pooled area under the curve was 0.62 (95% CI: 058–0.69). 
Also, the area under curve (AUC) was 0.66 (95% CI 
0.61–0.70), as shown in Figure 5. The ROC curve was 
symmetrical and the AUC was 0.66, which presents an 
advanced diagnostic accuracy for diagnosing of various 
cancers.The results reveal that lncRNA PCAT-1 have an 
advanced diagnostic value for esophageal squamous cell 
carcinoma, colorectal, prostate, hepatocellular carcinoma 
and gastric cancers. 
Discussion
Aberrant expression of some lncRNAs has been 
demonstrated to be associated with tumor progression, 
as well as with the clinical outcome in various cancers 
(Xue et al., 2016; Qian et al., 2017; Su et al., 2017; Zhuo 
and Kang., 2017). Until recently, lncRNA PCAT-1 has 
been considered as an potential diagnostic/ prognostic 
biomarker in a wide variety of neoplasms, including 
ovarian cancer (Qian et al., 2017; Cao et al., 2014), 
prostate cancer (Karlsson et al., 2016; Chandra Gupta 
et al., 2017), colorectal cancer (Qi et al., 2013; Xu et 
al., 2017), non-small-cell lung cancer (NSCLC), and 
esophageal squamous cell carcinoma (ESCC) (Shi et 
al., 2015). Lnc-PCAT-1 was firstly known as a prostate-
specific regulator of cell proliferation correlated with the 
degree of cell differentiation. Also, it was characterized 
as a main kind of lncRNA transcribed from the introns 
of known genes (Reis et al., 2004; Ren et al., 2013). 
The integrative analysis showed that PCAT-1, among 
other dysregulated lncRNAs, is a potential candidate 
lncRNA regulated by noncoding risk-associated SNPs 
in prostate cancer (Guo et al., 2016). An extensive study 
using RNA-Seq on prostate tissues and cells lines was 
completed previously (Prensner et al., 2011). They used 
a transcriptome assembly method to find out unannotated 
ncRNAs. Moreover, they recognized several dysregulated 
ncRNAs uncharacterized in prostate cancer (Prensner et 
al., 2011). Their result revealed the function of ncRNA 
transcriptome and confirmed dysregulation of three 
important target genes, BRCA2, CENPE and CENPF 
in prostate cancer. Altogether, the findings supported 
the biological role of lnc PCAT-1 as a tumor suppressor 
lncRNA in prostate cancer (Prensner et al., 2011). Lnc 
PCAT-1 was also identified as a novel prostate-specific 
regulator of cell proliferation and target of the Polycomb 
repressive complex 2 (PRC2) (Prensner et al., 2011). 
Furthermore, it was suggested that PCAT-1 gene may 
be function as a novel mechanism of “BRCA-ness” in 
sporadic cancers (Prensner et al., 2014).
SENSITIVITY (95% CI)
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Figure 5. Summary Receiver Operating Characteristic 
Curves (SROC) for lncRNA PCAT-1 Expression Outline 
in the Diagnosis of Several Cancers. Every circle 
represents an included study.
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The full texts of 5 articles among a total of 50 eligible 
studies were reviewed in order to meet the selection 
requirements for inclusion. In the systematic review and 
meta-analysis, it was attempted to collect all published 
papers assessing the prognostic significance of long non-
coding RNA PCAT-1 dysregulation in several cancers. The 
meta-analysis was carried out on overall survival (OS) in 
several carcinomas, including colorectal (CRC), gastric 
(GC), hepatocellular carcinoma (HCC), breast, bladder, 
and lung cancer, extrahepatic cholangiocarcinoma, 
multiple myeloma (MM) and esophageal squamous cell 
carcinoma (ESCC). This is the first systematic review and 
meta-analysis in the field.
The analyses showed that the patients with high 
lncRNA PCAT-1 expression had evidently poorer overall 
survival rates than those with low PCAT-1 expression. 
The PCAT-1 expression level in the aforementioned 
malignancies was associated with metastasis, histologic 
grade and TNM stage. The findings revealed that PCAT-
1 expression could be a potential diagnostic target in 
patients with colorectal (CRC), gastric, breast, bladder, 
lung cancer, and hepatocellular carcinoma, extrahepatic 
cholangio carcinoma, multiple myeloma and esophageal 
squamous cell carcinoma (ESCC). 
This lncRNA was firstly reported to overexpress in 
prostate cancer and established to relate with prognosis 
of disease. LncRNA PCAT-1 has been demonstrated to 
promote cell proliferation through binding to polycomb 
repressive complex 2 (PCR2) as a transcriptional 
repressor. Based on functional experiments, lnc PCAT-
1 was suggested as a potential therapeutic target for 
prostate cancer. Recently, the study of the expression 
levels of PCAT-1 in CRC tissues and matched adjacent 
normal tissues revealed that there is a correlation between 
PCAT-1 overexpression and the progression of CRC. 
This increased level of PCAT-1 was also associated with 
patients’ survival rate (Bi et al., 2017).
PCAT-1 also was shown to up-regulate in CRC 
tissues and correlate with overall survival and lymph 
node metastasis in cancer patients. Multivariate analysis 
demonstrated PCAT-1 as an independent prognostic 
factor for CRC. Moreover, related findings presented a 
molecular mechanism by which PCAT- 1 is implicated 
in CRC progression, suggesting it as a proper target for 
adjuvant therapy (Prensner et al., 2014).
PCAT-1 could play an important role as predictive 
and prognostic biomarker in some human solid tumors. 
However, there are some limitations to explain the results 
of this meta-analysis, although PCAT-1 was considered 
not only as potential independent predictive biomarker in 
survival of cancer patients. For example, there are only 
five studies in our study and all patients were Chiness 
population, it means that our results can be appropriate for 
Chinese population. Moreover, a significant heterogeneity 
in some clinicopathological characteristic was revealed. 
It means that there are needs to more studies with well-
designed and larger-size. 
Abbreviations
CRC: colorectal  cancer;  EMT: Epithel ial-
mesenchymaltransition; lincRNA, long intergenic non-
coding RNA, MM: Multiple myeloma, ECC: Extrahepatic 
cholangiocarcinoma, PARP-1: Poly [ADP-ribose] 
polymerase 1, NSCLC:Non-small-cell lung carcinoma.
Conflict of interest
The authors declare that there are no conﬂicts of 
interest.
Acknowledgments
This work was supported by Iran University of Medical 
Sciences.
References
Adams BD, Parsons Ch, Walker L, et al (2017). Targeting 
noncoding RNAs in disease. J Clin Invest, 127, 761-71.
Beermann J, PiccoliMT, Viereck J,Thum T (2016). Non-coding 
RNAs in development and disease: background, mechanisms, 
and therapeutic approaches. Physiol Rev, 96, 1297-1325.
Bi M, Yu H, Huang B, Tang C (2017). Long non-coding 
RNA PCAT-1 over-expression promotes proliferation 
and metastasis in gastric cancer cells through regulating 
CDKN1A. Gene, 626, 337–43.
Cao J (2014).The functional role of long non-coding RNAs and 
epigenetics. Biol Proced Online, 42, 1-13.
Chandra Gupta S, Nandan Tripathi Y (2017). Potential of long 
non-coding RNAs in cancer patients: From biomarkers to 
therapeutic targets. In J Cancer, 140, 1955-67.
Cui W, Wu Y, Qu H (2017). Up-regulation of long non-coding 
RNA PCAT-1 correlates with tumor progression and poor 
prognosis in gastric cancer. Eur Rev Med Pharmacol Sci, 
21, 3021-7.
Evans J, PrensnerJ, ChenW, et al (2014).The long noncoding 
RNA PCAT-1 promotes prostate cell proliferation through 
posttranscriptional stabilization of the cMyc oncogene. Int 
J Radiat Oncol Biol Phys, 90, S90.
Ge X, ChenY, LiaoX, et al (2013). Overexpression of long 
noncoding RNA PCAT-1 is a novel biomarker of poor 
prognosis in patients with colorectal cancer. Med Oncol, 
30, 588.
Guo H, AhmedM, ZhangF, et al (2016). Modulation of 
long noncoding RNAs by risk SNPs underlying genetic 
predispositions to prostate cancer. Nat Genet, 48, 1142-50.
Huang J, DengG, Liu T, et al (2018). Long noncoding RNA 
PCAT-1 acts as an oncogene in osteosarcoma by reducing 
p21 levels. Biochem Biophys Res Commun, 495, 2622-9.
Karlsson O, Baccarelli AA (2016). Environmental health and 
long non-coding RNAs. Curr Environ Health Rep, 3, 178-87.
Li X, CaoY,Gong X,et al (2017).Long noncoding RNAs in head 
and neck cancer. Oncotarget, 8, 10726.
LiuL, LiuY, ZhuangC, et al (2015). Inducing cell growth arrest 
and apoptosis by silencing long non-coding RNA PCAT-1 
in human bladder cancer. Tumor Biol, 36, 7685-9.
Ma T, ZhouL, XiaJ, et al (2018). LncRNA PCAT-1 regulates 
the proliferation, metastasis and invasion of cervical cancer 
cells. Eur Rev Med Pharmacol Sci, 22, 1907-13.
Parikshak NN, Swarup V, Belgard TG, et al (2016). Genome-wide 
changes in lncRNA, splicing, and regional gene expression 
patterns in autism. Nature, 540, 423-7.
Prensner JR,Chen W, Han S, et al (2014). The long non-coding 
RNA PCAT-1 promotes prostate cancer cell proliferation 
through cMyc. Neoplasia, 16, 900-8.
Prensner JR, ChenW, Iyer MK, et al (2014). PCAT-1, a long 
noncoding RNA, regulates BRCA2 and controls homologous 
Atefeh Talebi et al
Asian Pacific Journal of Cancer Prevention, Vol 20674
recombination in cancer. Cancer Res, 74, 1651-60.
Prensner JR, IyerMK, BalbinOA, et al (2011). Transcriptome 
sequencing identifies PCAT-1, a novel lincRNA implicated 
in prostate cancer progression. Nat Biotechnol, 29, 742.
Prensner JR, IyerMK, BalbinOA, et al (2011). Transcriptome 
sequencing across a prostate cancer cohort identifies PCAT-1, 
an unannotated lincRNA implicated in disease progression. 
Nat Biotechnol, 29, 742-9.
Qi P, Xu Md, Ni Sj, et al (2013). Low expression of LOC285194 
is associated with poor prognosis in colorectal cancer. 
J Transl Med, 11, 122.
Qian Y, Liu D, Cao S, et al (2017). Upregulation of the long 
noncoding RNA UCA1 affects the proliferation, invasion, 
and survival of hypopharyngeal carcinoma. Mol Cancer, 
16, 68.
Qiao L, LiuX, TangY, et al (2017). Down regulation of the 
long non-coding RNA PCAT-1 induced growth arrest and 
apoptosis of colorectal cancer cells. Life Sci, 188, 37-44.
Qiao L, Liu X, Tang Y, et al (2018). Knockdown of long 
non-coding RNA prostate cancer-associated ncRNA transcript 
1 inhibits multidrug resistance and c-Myc-dependent 
aggressiveness in colorectal cancer Caco-2 and HT-29 cells. 
Mol Cell Biochem, 441, 99-108.
Qin HD, LiaoXY, ChenYB, et al (2016). Genomic characterization 
of esophageal squamous cell carcinoma reveals critical genes 
underlying tumorigenesis and poor prognosis. Am J Hum 
Genet, 98, 709-727.
Reis EM, Nakaya HI, Louro R, et al (2004). Antisense intronic 
non-coding RNA levels correlate to the degree of tumor 
differentiation in prostate cancer. Oncogene, 23, 6684-92.
Ren S, Wang F, Shen J, et al (2013). Long non-coding RNA 
metastasis associated in lung adenocarcinoma transcript 1 
derived miniRNA as a novel plasma-based biomarker for 
diagnosing prostate cancer. Eur J Cancer Care, 49, 2949-59.
Sarrafzadeh S, Geranpayeh L, Ghafouri-Fard S (2017). 
Expression analysis of long non-coding PCAT-1in breast 
cancer. Int J Hematol Oncol Stem Cell Res, 11, 185-91.
Saus E, Brunet-Vega A, Iraola-Guzmán S, et al (2016). Long 
non-coding RNAs as potential novel prognostic biomarkers 
in colorectal cancer. Front Genet, 7, 54. 
Shen X, Zhang Y, Wu X, et al (2017). Upregulated lncRNA-PCAT1 
is closely related to clinical diagnosis of multiple myeloma 
as a predictive biomarker in serum. Cancer Biomark, 18, 
257-63.
Shi Wh, WuQq, Li Sq, et al (2015). Upregulation of the long 
noncoding RNA PCAT-1 correlates with advanced clinical 
stage and poor prognosis in esophageal squamous carcinoma. 
Tumor Biol, 36, 2501-7.
Su J, Zhang E, Han L, et al (2017). Long noncoding RNA 
BLACAT1 indicates a poor prognosis of colorectal cancer 
and affects cell proliferation by epigenetically silencing of 
p15. Cell Death Dis, 8, e2665.
Wang Z, JinY, Ren HX, et al (2016). Downregulation of the 
long non-coding RNA TUSC7 promotes NSCLC cell 
proliferation and correlates with poor prognosis. Am J Transl 
Res, 8, 680-7.
Wen J, Xu J,Sun Q, Xing C, Yin W (2016). Upregulation of long 
non coding RNA PCAT-1 contributes to cell proliferation, 
migration and apoptosis in hepatocellular carcinoma. Mol 
Med Rep, 13, 4481-6.
Xu J, Zhao J, Zhang R (2017). The novel long noncoding RNA 
TUSC7 inhibits proliferation by sponging miR-211 in 
colorectal cancer. Cell Physiol Biochem, 41, 635-44.
Xu T, Hu XX, Liu XX, et al (2017). Association between SNPs in 
long non-coding RNAs and the risk of female breast cancer 
in a Chinese population. J Cancer, 8, 1162-9.
Xu W, Chang J,Du X, Hou J (2017). Long non-coding RNA 
PCAT-1 contributes to tumorigenesis by regulating FSCN1 
via miR-145-5p in prostate cancer. Biomed Pharmacother, 
95, 1112-8.
Xue D, Zhou C, Lu H, et al (2016). LncRNA GAS5 inhibits 
proliferation and progression of prostate cancer by targeting 
miR-103 through AKT/mTOR signaling pathway. Tumor 
Biol, 37, 16187-97.
Yan TH, Yang H, Jiang JH, et al (2015). Prognostic significance 
of long non-coding RNA PCAT-1 expression in human 
hepatocellular carcinoma. Int J Clin Exp Pathol, 8, 4126-31.
Zhang D, Cao J, Zhong Q, et al (2017). Long noncoding 
RNA PCAT-1 promotes invasion and metastasis via the 
miR-129-5p-HMGB1 signaling pathway in hepatocellular 
carcinoma. Biomed Pharmacother, 95, 1187-93.
Zhang F, Wan M, Xu Y, et al (2017). Long noncoding RNA 
PCAT1 regulates extrahepatic cholangiocarcinoma 
progression via the Wnt/β-catenin-signaling pathway. 
Biomed Pharmacother, 94, 55-62.
Zhang Q, Matsuura K, Kleiner DE, et al (2016). Analysis of long 
noncoding RNA expression in hepatocellular carcinoma of 
different viral etiology. J Transl Med, 14, 328.
Zhao B, Hou X, Zhan H (2015). Long non-coding RNA PCAT-
1 over-expression promotes proliferation and metastasis 
in non-small cell lung cancer cells. Int J Clin Exp Med, 8, 
18482-7.
Zhen Q, Gao LN, Wang RF, et al (2018). LncRNA 
PCAT-1 promotes tumour growth and chemoresistance of 
oesophageal cancer to cisplatin. Cell Biochem Funct, 36, 
27-33.
Zhuo W, Kang Y(2017). Lnc-ing ROR1-HER3 and Hippo 
signalling in metastasis. Nat Cell Biol, 19, 81-3.
This work is licensed under a Creative Commons Attribution-
Non Commercial 4.0 International License.
